Amicus Therapeutics (FOLD) Downgraded by BidaskClub to Sell

Share on StockTwits

BidaskClub lowered shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a sell rating in a report published on Wednesday, BidAskClub reports.

A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald set a $20.00 price objective on shares of Amicus Therapeutics and gave the company a buy rating in a report on Wednesday, May 8th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a sell rating to a hold rating in a report on Friday, May 3rd. Robert W. Baird set a $20.00 price objective on shares of Amicus Therapeutics and gave the company a buy rating in a report on Monday, April 22nd. Janney Montgomery Scott assumed coverage on shares of Amicus Therapeutics in a report on Friday, April 5th. They set a buy rating and a $13.91 price objective for the company. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a hold rating to a buy rating in a report on Friday, March 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $18.19.

FOLD stock opened at $12.18 on Wednesday. Amicus Therapeutics has a 12 month low of $8.27 and a 12 month high of $17.62. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a market cap of $2.81 billion, a P/E ratio of -9.16 and a beta of 1.79.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.09). Amicus Therapeutics had a negative net margin of 386.18% and a negative return on equity of 64.11%. The company had revenue of $34.00 million for the quarter, compared to the consensus estimate of $37.82 million. The company’s revenue for the quarter was up 103.6% on a year-over-year basis. As a group, research analysts expect that Amicus Therapeutics will post -1.33 earnings per share for the current year.

In other news, insider Jay Barth sold 50,000 shares of the business’s stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the completion of the sale, the insider now owns 179,767 shares in the company, valued at approximately $2,552,691.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO John F. Crowley sold 20,000 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $13.60, for a total transaction of $272,000.00. Following the completion of the sale, the chief executive officer now owns 678,844 shares of the company’s stock, valued at approximately $9,232,278.40. The disclosure for this sale can be found here. Insiders have sold a total of 180,000 shares of company stock valued at $2,401,200 in the last quarter. 2.90% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the company. Strs Ohio raised its holdings in shares of Amicus Therapeutics by 56.0% in the 4th quarter. Strs Ohio now owns 3,900 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,400 shares in the last quarter. Sage Capital Advisors llc raised its holdings in shares of Amicus Therapeutics by 13.8% in the 4th quarter. Sage Capital Advisors llc now owns 12,400 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 1,500 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Amicus Therapeutics by 3.5% in the 1st quarter. Principal Financial Group Inc. now owns 54,227 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 1,820 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Amicus Therapeutics by 117.9% in the 4th quarter. Bank of Montreal Can now owns 3,428 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,855 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC raised its holdings in shares of Amicus Therapeutics by 8.9% in the 1st quarter. Quantitative Systematic Strategies LLC now owns 27,924 shares of the biopharmaceutical company’s stock valued at $380,000 after purchasing an additional 2,283 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Featured Article: Return on Investment (ROI)

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Autoliv  PT Lowered to $62.00 at Buckingham Research
Autoliv PT Lowered to $62.00 at Buckingham Research
Shotspotter  Cut to “Market Perform” at Northland Securities
Shotspotter Cut to “Market Perform” at Northland Securities
Buckingham Research Increases Sonic Automotive  Price Target to $20.00
Buckingham Research Increases Sonic Automotive Price Target to $20.00
Vail Resorts  Earns Market Perform Rating from Analysts at Wells Fargo & Co
Vail Resorts Earns Market Perform Rating from Analysts at Wells Fargo & Co
Johnson Outdoors  Downgraded by Sidoti
Johnson Outdoors Downgraded by Sidoti
Autoliv  Stock Rating Upgraded by Robert W. Baird
Autoliv Stock Rating Upgraded by Robert W. Baird


© 2006-2019 Ticker Report